Belatacept vs anticalcineurins after kidney transplant
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study is comparing two medications after kidney transplant: Belatacept and anticalcineurins (like tacrolimus). It looks at how each affects blood vessel health. If you are more than a year post-transplant and have stable kidney function, you may be eligible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 1 year post-kidney transplant.
- Your age must be between 18 and 75 years old.
- If you are on anticalcineurins (like tacrolimus), your kidney function must be stable (no big changes in creatinine for 3 months).
- If you switched to Belatacept due to a kidney biopsy showing damage from anticalcineurins, you may also qualify.
- You cannot have had a heart attack or stroke in the last 6 months, or have severe heart failure.
- You must not be on dialysis or have severely reduced kidney function (GFR below 15).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether belatacept can help prevent damage in kidney transplant recipients who develop new antibodies against their donor kidney. It is for people whose kidney function is still stable, which may allow treatment to slow or stop antibody-related injury.
This study looks at how well a once-daily anti-rejection medicine (Envarsus) works in people who have just had a kidney transplant. It helps doctors understand the best way to use this medicine and manage side effects.
This trial looks at replacing standard anti-rejection medicines (tacrolimus, a type of CNI, plus mycophenolate and possibly prednisone) with belatacept in adults who have early kidney graft dysfunction 3–12 months after a kidney transplant. It aims to see if belatacept can control rejection and protect kidney function in the right patients.
This trial studies whether belatacept can be used after a heart transplant to help protect kidney function over time. It focuses on people who already have (or are at risk for) worsening kidney function after transplant, while avoiding those with certain infections or rejection concerns.
This study tests a drug called belatacept, which may help prevent the body from rejecting a new heart. It is given after a heart transplant, and the goal is to see if it works as well as or better than standard anti-rejection medicines.
This Phase 2 study looks at whether blood test “biomarkers” can guide safely changing anti-rejection medicines after an ABO-compatible kidney transplant. It may help some people reduce certain medicines while keeping the new kidney protected from rejection.
Hear when a new Kidney Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.